Reaction
Vein Rupture reporting signals
As of the last recalculation, Vein Rupture appears in 1,650 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 53.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 115 | 53.3 | 53.5 |
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 56 | 34.2 | 34.3 |
| Hydrocortisone Sodium Succinate | 17 | 23.0 | 23.1 |
| Dimenhydrinate | 17 | 20.3 | 20.4 |
| Human Immunoglobulin G | 31 | 19.3 | 19.3 |
| Iron Sucrose | 14 | 18.7 | 18.7 |
| Diphenhydramine | 80 | 16.7 | 16.8 |
| Adrenalinum | 51 | 16.0 | 16.0 |
| Agalsidase Beta | 10 | 13.7 | 13.7 |
| Diphenhydramine Hydrochloride | 138 | 11.4 | 11.4 |
| Sodium Chloride | 67 | 11.1 | 11.1 |
| Sodium Chloride Tablet | 62 | 11.0 | 11.0 |
| Sodium Chloride Tablets | 62 | 11.0 | 11.0 |
| Epinephrine | 53 | 10.5 | 10.5 |
| Infliximab | 153 | 9.6 | 9.6 |
| Vedolizumab | 60 | 9.1 | 9.1 |
| Ribociclib | 21 | 8.5 | 8.5 |
| Mesalamine | 36 | 8.2 | 8.2 |
| Ravulizumab | 8 | 7.5 | 7.5 |
| Belimumab | 17 | 6.8 | 6.8 |
| Ustekinumab | 52 | 6.6 | 6.6 |
| Travoprost | 4 | 5.8 | 5.8 |
| Alpelisib | 4 | 5.8 | 5.8 |
| Risankizumab-Rzaa | 34 | 5.3 | 5.3 |
| Secukinumab | 65 | 5.2 | 5.3 |
| Emicizumab | 5 | 5.1 | 5.1 |
| Upadacitinib | 32 | 5.0 | 5.0 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 4.8 | 4.8 |
| Natalizumab | 60 | 4.3 | 4.3 |
| Ixekizumab | 10 | 3.4 | 3.4 |